CD274 and non-small cell lung carcinoma: Current efforts are focused on establishing these agents as first line therapy in various phase 3 studies, either as monotherapy in PD-L1 positive NSCLC (CheckMate 026 NCT02041533, KEYNOTE-024 NCT02142738, MYSTIC NCT02453282) or in combination with ipilimumab or chemotherapy (CheckMate 227 NCT02477826, KEYNOTE-189 NCT02578680, KEYNOTE-407 NCT02775435, NEPTUNE NCT02542293, Impower 132 NCT02657434, Impower 150 NCT02366143).